Alzheimer’s disease (AD) and Parkinson’s disease (PD), represent major global public health challenges, and a large proportion of patients go undiagnosed. Early diagnosis is beneficial for patients and carers and can result in substantial cost savings to healthcare systems. Current diagnostic measures are unscalable, expensive and time-consuming and thus have limited accessibility as frontline diagnostic tools. 

PANDA will address these needs and develop and assess a wearable solution that can measure and analyze subtle changes in sleep and autonomic function, instrumental for precision medicine and early biomarkers of neurodegeneration, thus moving from current reactive diagnostic options to early detection, protection and prevention.
Precision medicine is the tailoring of treatment to the individual patient, by stratifying patients into subgroups with more homogenous profiles and treatment responses. PANDA aims to enable precision medicine at scale by developing a solution that can measure and analyze subtle changes in central nervous system activity. The project will advance existing ear-EEG platforms by integrating additional sensor, and develop algorithms to extract pathophysiological information from the sensor signals. The goal is to provide a method for future clinical studies and enable precision medicine at scale towards an unobtrusive and cost-efficient diagnostics of neurodegenerative diseases.

• Danish Center for Sleep Medicine
• Copenhagen University Hospital (Rigshospitalet)
• T&W Engineering
• Institute of Cognitive Neuroscience
• UCL